Mark A. Hayden


Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.


Mark Hayden is a litigation associate in the firm’s New York office. His practice focuses on intellectual property litigation with a particular emphasis on representing clients in the pharmaceutical and biotechnology industries. Mark is also registered to practice before the US Patent and Trademark Office. He has significant experiencing litigating under the Hatch-Waxman Act and has played key roles in fact and expert discovery, depositions, and trial.

Before attending law school, Mark worked in a research laboratory at Brigham and Women’s Hospital/Harvard Medical School focused on using next generation sequencing (NGS) technologies to elucidate the molecular and genetic underpinnings of cancers, gynecological diseases, and human developmental disorders.



Bar Admissions

  • New York

Registered to Practice

  • US Patent & Trademark Office


  • Boston College, J.D.: Managing Editor, Boston College Law Review
  • College of William & Mary, B.B.A., Finance; Biochemistry Minor: Research Fellow, Dept. of Neuroscience

Professional Activities


  • The Burgeoning “Biorights Movement”: Its Legal Basis, What’s at Stake, and How to Respond. 59 Boston College Law Review 1775 (2018).
  • Clinical, Pathologic, Cytogenetic, and Molecular Profiling in Self-Identified Black Women with Uterine Leiomyomata. Cancer Genetics 2018; 222-223:1–8. PubMed PMID 29666002.
  • The Genomic Landscape of Balanced Cytogenetic Abnormalities Associated with Human Congenital Anomalies. Nature Genetics 2017; 49(1):36–45. PubMed PMID 27841880.
  • Structural Chromosomal Rearrangements Require Nucleotide-Level Resolution: Lessons from Next-Generation Sequencing in Prenatal Diagnosis. American Journal of Human Genetics 2016; 99(5): 1015–1033. Pubmed PMID 27745839.


  • Honorable Katharine S. Hayden, U.S. District Judge for District of New Jersey (Summer 2016)


  • New York Intellectual Property Law Association
  • American Bar Association